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In the immune system’s tug of war with cancer, tolerance mechanisms by which the tumor can 
control anti-tumor immune responses play a central role in determining the outcome. 
Regulatory T cells (Treg) induced in the thymus or the periphery, represent one such tolerance 
mechanism that potentially can be exploited by developing tumors. In this thesis, we explore 
the underlying molecular mechanisms that result in Treg development, and attempt to elucidate 
the importance of this T lymphocyte subset in urinary bladder cancer. 
In humans and mice, the transcription factor FOXP3 is crucial for the function of the Treg 
subset and maintenance of peripheral tolerance, as illustrated by the lack of functional Treg and 
autoimmune disorders that result from mutations within this protein. In humans however, 
clinical studies of this important T lymphocyte subset are obscured by the fact that FOXP3 is 
transiently induced in conventional T lymphocytes upon activation. Initially, we address the 
epigenetic regulation of FOXP3 expression, and demonstrate that the committed Treg 
population has an almost completely demethylated FOXP3 promoter region, whereas 
conventional non-regulatory CD4+ T lymphocytes are semi-methylated in this region. 
Furthermore, we study the development of regulatory T cells in mice, and assess the 
contribution and the impact of adenosine receptor signaling on the T lymphocyte compartment. 
Next, the role of the Treg population in urinary bladder cancer is evaluated. First, we investigate 
the impact of tumor infiltrating CD3+ as well as FOXP3+ T lymphocytes on patient survival. 
Somewhat surprisingly, we find a positive correlation between both CD3+ and FOXP3+ 
lymphocytic infiltrates, suggesting that FOXP3+ lymphocytes in this case may not represent a 
tumor escape mechanism as initially hypothesized. In addition, we observe FOXP3 expression 
in a subset of tumors, and find that this expression is a negative prognostic factor for survival. 
To follow up these results, we characterize the T lymphocyte immune response in peripheral 
blood, lymph nodes and tumor tissue from patients with UBC. We demonstrate that the 
FOXP3+ fraction of CD4+ T lymphocytes is significantly increased compared to all other 
locations investigated including macroscopically healthy bladder tissue. Furthermore, these 
tumor infiltrating lymphocytes express high levels of activation and effector markers, but do 
not display a demethylated pattern in the FOXP3 promoter to match its prominent expression. 
Interestingly, muscle invasive tumors have a lower FOXP3+ fraction at the invasive front 
compared to non-invasive counterparts. In addition, we observe changes in the cellular immune 
response dependent on if the patients have received neo-adjuvant chemotherapy or not, both 
with regard to cell composition and functional reactivity to tumor antigens. 
Epigenetic regulation governs the commitment of T lymphocytes to the Treg lineage. The fact 
that FOXP3 expressing tumor infiltrating lymphocytes in UBC do not display a committed 
Treg phenotype could potentially explain the differences in reported clinical impact of this 
population in different cancers and has implications for future immunotherapy. 
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1 INTRODUCTION 
The human body hosts an intriguingly complex balance, and ever ongoing battle of sovereignty. 
Constantly challenged by external pathogens, the immune system has evolved to recognize and 
eliminate possible threats while sparing and caring for autologous tissues. In this setting, the 
two main branches of the immune response, innate and adaptive immunity, play integral and 
complementary parts. By means of their broad specificity but limited repertoire of pattern 
recognition receptors (PRRs), innate immune cells are constantly vigilant for danger signals 
(damage associated molecular patterns (DAMPs) and pathogen associated molecular patterns 
(PAMPs)), ready to quickly initiate a primary immune response upon stimulation (Kono and 
Rock, 2008). In contrast, T- and B-lymphocytes carry receptors with an almost unlimited 
potential to recognize foreign antigens, but react slower compared to their innate counterparts. 
At the intersection of these two responses is the presentation of antigens to T lymphocytes by 
antigen presenting cells (APCs) (Figure 1); an essential process for the initiation of an adaptive 
immune response. The context of the antigen presentation determines the outcome of the 
ensuing T lymphocyte response, where presence of co-stimulatory molecules on the APC in 
combination with the cytokine milieu facilitates and directs the type of T lymphocyte response. 
Since the T lymphocyte receptor repertoire contains approximately in the range of 109-1015 
specificities with potential to theoretically recognize any protein epitope, the distinction of self 
is essential to avoid autoimmunity. This distinction and thus protection of autologous tissue is 
ensured by two separate mechanisms – central and peripheral tolerance. For T lymphocytes, 
central tolerance is molded in the thymus, where T lymphocytes carrying T cell receptors 
(TCR) with high affinity to self-proteins are deleted (Palmer, 2003) (further discussed in 
section 1.1). In the periphery, potentially autoreactive T lymphocytes are kept in check by 
different peripheral tolerance mechanisms (Abbas et al., 2004). The most straightforward 
mechanism is the concept of ignorance where potentially self-reactive T lymphocytes remain 
inactive because of low levels of or no accessibility to the antigen. Secondly, in the absence of 
danger signals, the APC will not upregulate the co-stimulatory molecules required by naïve T 
lymphocytes for activation. TCR ligation in the absence of co-stimulation leads to anergy or 
deletion and thus protects from autoimmunity (Redmond and Sherman, 2005). Alternatively, 
engagement of B7 costimulatory molecules on the APC to cytotoxic T lymphocyte antigen 4 
(CTLA-4) on the T lymphocytes instead of its stimulatory counterpart CD28, may also induce 
T cell tolerance (Perez et al., 1997). Furthermore, regulatory T cells (Tregs) induced 
peripherally or in the thymus, can regulate the immune response and thus maintain tolerance 
(Sakaguchi et al., 2010). 
Cancer poses a unique threat to the human body in the sense that it is inherently both self and 
non-self at the same time. Tumor evolution is shaped by the immune system, and successful 
tumors evade immune responses in various ways, including suppression of the local T 
lymphocyte responses and induction of tolerance (discussed in more detail in section 1.5). This 
thesis enacts at the interphase of physiology and tumor pathology, and concerns both the 
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development and regulation of regulatory T cells (papers I and IV) as well as their role and 
prognostic impact in urinary bladder cancer (UBC) (papers II and III). 
1.1 T LYMPHOCYTE SELECTION AND DIFFERENTIATION 
1.1.1 Thymic selection 
T lymphocyte progenitors migrate to the thymus from the bone marrow. During their 
development in the thymus, thymocytes undergo strict selection processes that only permits T 
lymphocytes with functional but not overtly self-reactive TCRs to exit the thymus. In the end, 
less than 5% of the initial thymocyte population is selected and allowed to leave for the 
periphery (Starr et al., 2003). Here follows a brief summary of the selection process for 
conventional α/β T lymphocytes. 
Newly arrived thymocytes are CD4-CD8- double negative (DN) and can be further subdivided 
into differentiation stages based on their expression of the markers CD44 and CD25 (Godfrey 
et al., 1993). While they migrate though the thymic cortex, thymocytes sequentially pass the 
CD44+CD25- (DN1), CD44+CD25+ (DN2), CD44-CD25+ (DN3) and CD44-CD25- (DN4) 
stages (Godfrey et al., 1993; Lind et al., 2001). Rearrangement of the TCR gene starts at the 
DN3 stage with the expression of the recombination activating genes (RAG 1 and 2), and 
rearrangement of the TCRβ locus. In a process called β selection, the rearranged TCRβ chain 
together with a pre-TCRα chain forms a pre-TCR complex, which triggers thymocyte 
proliferation, induction of the two TCR co-receptors CD4 and CD8, and rearrangement of the 
TCRα chain locus (Hoffman et al., 1996). CD4+CD8+ double positive (DP) thymocytes that 
 
Figure 1. Basic concept of naïve T helper lymphocyte activation. To become activated, a 
naïve T lymphocyte requires three distinct sets of signals. 1. TCR recognition of a peptide-
MHC complex. 2. Costimulatory signals. 3. Inflammatory cytokines. 
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successfully rearrange their TCRα chain to form a functional α/β TCR complex undergo 
positive selection based on their TCR affinity for MHC molecules on cortical thymic epithelial 
cells (cTEC). Failure to recognize self-MHC results in elimination by apoptosis, while 
positively selected cells down-regulate CD4 or CD8 expression based on their recognition of 
major histocompatibility complex class (MHC) I or MHC II respectively and migrate to the 
thymic medulla (Starr et al., 2003). Interestingly, the positive selection process goes on for 
several days during which it appears that thymocytes must receive continuous TCR signals 
with associated activation of the mitogen activated protein kinase (MAPK) pathway in order 
to pass this check point in development (McNeil et al., 2005; Wilkinson et al., 1995). 
Negative selection encompasses the process where T lymphocytes with TCRs that strongly 
recognize self peptide-MHC complexes are deleted. This is a crucial step in central T cell 
tolerance, preventing autoreactive T lymphocytes to exit the thymus to the periphery. Medullar 
thymic epithelial cells (mTECs) as well as thymic dendritic cells (tDCs) are key players at this 
check point, where presentation of a diverse repertoire of self-antigens on MHC-molecules in 
combination with co-stimulation drive the negative selection process (Palmer, 2003).  
1.1.2 T helper cell subsets 
Once outside the thymus T lymphocytes circulate the secondary lymphoid organs in search of 
APCs presenting their cognate antigen. If encountered in the context of co-stimulation and the 
appropriate cytokines, the naïve CD4+ T lymphocyte is activated as illustrated in Figure 1. The 
local cytokine milieu caused by the triggering factors, and inflammatory cell composition at 
the site of activation influences the type of T lymphocyte response that is elicited. The major 
T helper lineages that have been described include the classical T helper type 1 (Th1) and T 
helper type 2 (Th2) cells, primarily described as stable lineages involved in promoting cellular 
and humoral immune responses respectively. With time, new T helper lineages such as the 
Th17, Treg and T follicular helper (Tfh) have been characterized adding to the complexity of 
T helper differentiation. Intense studies of the factors that drive the evolution of each lineage 
have defined transcription factors essential for each subtype as; T-box transcription factor (T-
bet) for Th1, GATA3 for Th2, FOXP3 for Treg and Bcl-6 for Tfh (Weinmann, 2014). 
Interestingly, with the increasing number of T helper differentiation fates, reports describing 
the co-expression of hallmark cytokines such as IL-17 (Th17) and IFN-γ (Th1) in CD4+ T 
lymphocytes have emerged (Wilson et al., 2007). There are now also numerous reports of 
combined expression of the lineage defining transcription factors in various contexts (Oestreich 
and Weinmann, 2012). With regard to Treg cells, it is interesting to note that the co-expression 
of other lineage defining transcription factors such as T-bet and Bcl-6, have been implicated in 
the suppression of their respective type of immune response (here; Th1 and Tfh type responses 
respectively) (Koch et al., 2009; Linterman et al., 2011). These reports have challenged the 
established view of T helper lineages as stable final differentiation states, and suggested a more 
dynamic model of T helper differentiation (Weinmann, 2014). In this setting, the ever changing 
stimuli that a T cell encounters in combination with its epigenetic and protein phenotype (that 
is a consequence of its previous history) will finally determine the type of response elicited. 
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1.2 REGULATORY T CELLS 
Regulatory T cells play an integral part in the control of immune responses. The fact that the T 
lymphocyte compartment contains cells capable of controlling immune responses has been 
known to the scientific community since the early 1970’s (Sakaguchi et al., 2007). At the time 
generally known as suppressor T cells, this population attracted strong attention during the 
following years, but was finally abandoned much due to the lack of good phenotypic markers 
(Sakaguchi et al., 2007). In the mid 1990’s however, the field was revived with Sakaguchi’s 
classical report describing the regulatory properties of a subpopulation of CD4+ T lymphocytes 
that constitutively expressed the α-chain of the interleukin-2 receptor (IL-2Rα, CD25) 
(Sakaguchi et al., 1995). Since then, this population has been the focus of intense research, and 
although the knowledge about Treg properties and subtypes has greatly improved, much 
remains to be elucidated. Here follows a brief summary of main markers, subsets, and 
mechanisms of action of CD4+FOXP3+ Tregs dealt with in this thesis. 
1.2.1 Regulatory T cell lineage markers 
Numerous molecular markers have been suggested for the delineation of the Treg subsets, some 
of which have already been mentioned. The following subsections will discuss some of the 
most commonly used markers, with a main focus on the markers used in this thesis. 
1.2.1.1 CD25 
As mentioned previously, the Treg population was first defined as a subpopulation of CD4+ T 
lymphocytes that expressed the IL-2 receptor α-chain (CD25) constitutively (Sakaguchi et al., 
1995). Together with the β-chain (CD122) and the common cytokine receptor γ-chain 
(CD132), CD25 forms the high-affinity IL-2R. Interestingly, IL-2R signaling has been shown 
to be important for the development and maintenance of Treg (Thornton, 2006). In humans, 
Baecher-Allan et al. showed that only the CD25high population (corresponding to between 1 
and 2% of CD4+ T lymphocytes in peripheral blood) correlated with suppressive capacity 
whereas the CD25low/intermediate cells did not suppress T lymphocyte proliferation (Baecher-Allan 
et al., 2001). However, CD25 is upregulated in T cells upon activation, and although CD25 
expression is subsequently lost again when the stimulus is removed, this fact decreases its 
specificity and usefulness as a marker in clinical settings. 
Figure 2. Treg lineage markers. Diagram 
depicting markers preferentially expressed by 
Tregs. CD25, CD127, CTLA-4, CD39, FOXP3 
and HELIOS are discussed more in detail in the 
main text. Other markers, such as latency 
associated peptide (LAP)/GARP and GITR 
have also been associated with the Treg 
phenotype, however, a detailed discussion of 
all Treg associated molecules is not within the 
scope of this thesis.
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1.2.1.2 FOXP3 
The transcription factor FOXP3 has been linked to the suppressive phenotype of both human 
(FOXP3) and murine (Foxp3) Treg populations (Sakaguchi et al., 2010). Its close relationship 
to the Treg population was first proposed in the Scurfy mouse model, and soon thereafter 
confirmed by the fact that the human disease Immune dysregulation, Polyendocrinopathy, 
Enteropathy, X-linked syndrome (IPEX) was associated with mutations in the FOXP3 gene 
(Bennett et al., 2001; Brunkow et al., 2001). In mice, Foxp3 is generally considered to be a 
specific, required and sufficient factor for Treg development (Fontenot et al., 2003). In humans 
however, FOXP3 is not as specific since it is transiently upregulated in human CD4+CD25low 
T lymphocytes upon activation (Walker et al., 2003). Although this expression is associated 
with hypo-responsiveness and decreased cytokine production (Wang et al., 2007), results have 
differed regarding the in vitro suppressive capacity of the T lymphocytes with induced FOXP3 
expression (Walker et al., 2003; Wang et al., 2007), and it seems that a stable FOXP3 
expression is required for suppressive function. Indeed, in vitro induced FOXP3 expression in 
conventional human T lymphocytes does confer a regulatory phenotype (Allan et al., 2005; 
Walker et al., 2005), and the level of suppressive capacity is both time and dose dependent as 
illustrated by a conditional expression model (Allan et al., 2008). 
In further contrast to the mouse setting, humans express different splice variants of FOXP3 
mRNA that lead to the expression of; full length FOXP3 (FOXP3fl), FOXP3 lacking exon 2 
(FOXP3Δ2), and FOXP3 lacking exon 2 and 7 (FOXP3Δ2Δ7) (Allan et al., 2005; Smith et al., 
2006). Although the FOXP3fl and FOXP3Δ2 isoforms have been reported to confer a Treg 
phenotype and regulatory activity in vitro (Aarts-Riemens et al., 2008; Smith et al., 2006) this 
does not seem to be the case for the FOXP3Δ2Δ7 isoform that instead appears to exert a 
dominant negative effect on FOXP3fl upon co-transduction (Mailer et al., 2009). In addition, 
it has been shown that the exon 2 domain in the full-length FOXP3 protein interacts with the 
transcription factor retinoic acid receptor-related orphan receptor (ROR) α and ROR γt, 
suppressing genes related to Th17 development in T lymphocytes, an effect not achieved by 
FOXP3Δ2 (Du et al., 2008; Ichiyama et al., 2008). Still, the physiological and clinical impact 
of these three isoforms remains to a large extent unknown. 
FOXP3 undeniably plays an essential role for the regulatory function of Tregs in both mice and 
men. However, the Treg transcriptional profile (in mice) has been demonstrated to be only 
partly dependent on Foxp3 expression (Hill et al., 2007). This was emphasized in other studies 
where T lymphocytes lacking suppressive capacity but with similar phenotypes to Treg 
developed in spite of missing functional Foxp3 (Lin et al., 2007). Together these findings 
indicate upstream events of Foxp3 expression as important factors in commitment to the Treg 
lineage. 
The transient expression of FOXP3 in activated human T lymphocytes combined with the 
human heterogeneity with regard to FOXP3 isoforms calls for caution in interpreting human 
Treg data based on FOXP3 expression alone, especially in clinical inflammatory settings where 
T cell activation is to be expected. 
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1.2.1.3 CD127 
Low expression of the IL-7 receptor α-chain (CD127) has been suggested as a complementary 
surface marker for Tregs (Liu et al., 2006; Seddiki et al., 2006). CD127 is downregulated in T 
lymphocytes upon activation, but whereas effector and memory T lymphocytes resume their 
expression, FOXP3+ Tregs remain CD127low/-. Although not perfect, this makes CD127 
especially interesting for in vivo studies of immune responses where activated T cells are 
expected. The study by Liu et al. related CD127 expression to FOXP3 and found that less than 
half of the CD4+CD127low/- population was FOXP3+ (Liu et al., 2006). Categorizing the Treg 
population based on CD25high cells did produce much more pure FOXP3+ populations but left 
out a considerable number of FOXP3+ Tregs in the CD25int→low population (Liu et al., 2006). 
The authors proposed instead that the combination of the two markers be used for surface based 
distinction of FOXP3+ cells as the CD4+CD25+CD127lo/- population, which leads to both 
improved purity and yield. 
1.2.1.4 CTLA-4 
The cytotoxic T lymphocyte antigen 4 (CTLA-4 or CD152) is another marker that has been 
used to identify the Treg population. It binds the same ligands as the co-stimulatory molecule 
CD28 (CD80/CD86 or B7.1/B7.2), but with higher affinity and provides a co-inhibitory signal 
(reviewed in (Murakami and Riella, 2014)). In contrast to CD28 which is constitutively 
expressed on most resting human T lymphocytes, CTLA-4 expression peaks within 48h of 
activation and is only constitutively expressed by the Treg subset (Murakami and Riella, 2014; 
Walunas et al., 1994). Its surface expression is tightly regulated and in unstimulated cells 
CTLA-4 is mainly localized to intracellular vesicles that upon T cell activation fuse with the 
cell membrane to be exposed on the cell surface preferably at the sites of TCR engagement 
(Linsley et al., 1996). CTLA-4 can interfere with immune activation through various 
mechanisms including the competitive binding of B7 molecules on APCs, interfering with the 
intracellular activation signals upon TCR stimulation and induction of regulatory mechanisms 
such as indoleamine 2, 3-dioxygenase (IDO) production by the APCs (Murakami and Riella, 
2014). 
1.2.1.5 Helios 
In addition to FOXP3, the ikaros family transcription factor Helios has been proposed as a 
complimentary marker for tTreg (Thornton et al., 2010). This study illustrated that Foxp3+ 
thymocytes are virtually all double positive for Helios, whereas the peripheral Treg 
compartment contained only approximately 70% Helios expressing cells. Moreover, they 
illustrated that in vitro induced murine and human iTregs do not express Helios (Thornton et 
al., 2010). Subsequent studies showed that Helios+FOXP3+ Treg displayed a more 
demethylated pattern in their FOXP3 gene compared to Helios- counterparts, suggesting that 
these indeed represent a committed Treg lineage (see below) (Kim et al., 2012). However, there 
have also been reports challenging Helios as a specific marker of tTreg (Akimova et al., 2011; 
Himmel et al., 2013). In one study, Akimova et al. found that Helios expression contrary to 
being Treg specific is predominantly associated to activated and proliferating cells (Akimova 
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et al., 2011). Furthermore, Helios’ specificity has been challenged based on the finding of 
Helios- Treg expressing markers of naïve T lymphocytes and recent thymic immigrants 
(Himmel et al., 2013). In contrast to the earlier studies described, none of the latter were able 
to find a correlation between FOXP3 methylation status and Helios expression. In conclusion, 
the fact remains that the peripheral CD4+FOXP3+ Treg compartment can be divided into two 
subsets based on the expression of the transcription factor Helios, however the functional 
significance of which at this point remains unresolved. 
1.2.2 Regulatory T cell subsets 
As a result of the great scientific interest in the Treg field over the past decades, the knowledge 
has vastly expanded together with the number of described Treg subtypes. In addition to the 
CD4+FOXP3+ Treg subsets that are the main focus of this thesis, other T lymphocyte 
subpopulations with regulatory properties have also been described including the peripherally 
IL-10 induced and producing Tr1 and transforming growth factor β (TGF-β) producing Th3 
cells as well as CD8+ Tregs (Buckner and Ziegler, 2004; Niederkorn, 2008). Although of great 
interest, a detailed discussion of these regulatory populations is beyond the scope of this thesis. 
Instead, the following sections will focus on Treg subsets defined by their expression of the 
hallmark transcription factor forkhead box P3 (FOXP3). Due to the immense attention that 
Tregs have received, the body of litterature on the subject has practically exploded during 
recent years together with the proposed number of Treg subsets. In an attempt to simplify the 
nomenclature, a group of leading scientists from different parts of the field suggested the 
concept of three main subgroups; namely thymus derived Treg (tTreg), peripherally derived 
Treg (pTreg) and in vitro induced Treg (iTreg) (Abbas et al., 2013). 
1.2.2.1 Regulatory T cell development 
The absolute requirement of the thymus for the development of Treg cells is perhaps best 
illustrated by animal models such as thymectomy of mice on postnatal day 2-4, which results 
in abrogated thymic Treg development and autoimmunity (Sakaguchi et al., 2007). Coherent 
with the timing of this model, under normal conditions in mice, CD4+CD25+Foxp3+ Treg are 
detectable in the periphery starting from around three days after birth. TCR interactions with 
MHC-peptide complexes on APCs together with co-stimulatory signals and cytokines are key 
players in Treg selection (Hsieh et al., 2012). The specificity of the Treg TCR repertoire has 
been the subject of debate during recent years. However, in general Treg appear to be selected 
much based on self-reactivity of their TCR, at an intermediate level between that of thymocytes 
that will mature to conventional T lymphocytes and those that will undergo negative selection 
due to too high TCR self-affinity (Hsieh et al., 2012). 
In the thymus, Foxp3+ thymocytes are found mainly in the medulla, driving the hypothesis that 
the Treg lineage is induced mainly in the thymic medulla (Fontenot et al., 2005a). In particular, 
mTECs expressing the autoimmune regulator (Aire) transcription factor have been implicated 
in the generation of Tregs, since absence of MHC II on these cells resulted in reduction in the 
number of Foxp3+ thymocytes in the medulla. Furthermore, the induced expression of a model 
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antigen in mTECs lead to the generation of Tregs specific for the antigen independently of 
medullar dendritic cells (Aschenbrenner et al., 2007). However, subsequent studies have shown 
that also bone marrow derived tDCs are capable of inducing Foxp3 independently of mTECs 
(Hsieh et al., 2012; Proietto et al., 2008). In addition, although the absolute majority of Foxp3+ 
thymocytes are found as CD4SP cells in the medulla, a few Foxp3+ cells are also observed at 
more immature thymocyte stages in the thymic cortex, and Treg development has been 
observed in mice with MHC II expression restricted to cTECs (Bensinger et al., 2001). Foxp3+ 
cells are in fact enriched in the late double positive development stage in the cortex, and the 
blocked migration of thymocytes resulted in accumulation of cortical Foxp3+ thymocytes 
suggesting that also cTEC may contribute to the induction of Tregs (Liston et al., 2008). In 
summary, thymic APCs play a crucial part during tTreg development, however, the 
contributions of each APC subtype is still a matter of investigation. 
Although the thymic development of Tregs has been studied intensely in mice, relatively little 
is known about the mechanisms that drive the development of tTreg in humans (Sakaguchi et 
al., 2010). Of note, in humans functional Tregs are present already from week 14 of gestation 
in contrast to the murine setting where Treg development is first detected after birth (Darrasse-
Jeze et al., 2005). Moreover, even if many parts of thymocyte development in humans and mice 
are comparable, the Hassal’s corpuscles are unique to the histology of the human thymus. 
Interestingly, studies have shown that the Hassal’s corpuscles produce thymic stromal 
lymphoprotein (TSLP) that is able to activate thymic DCs. These TSLP activated DCs were 
subsequently shown to induce FOXP3 expression in CD4SP CD25- thymocytes (Hanabuchi et 
al., 2010; Watanabe et al., 2005). Furthermore, in the thymic medulla thymocytes expressing 
Treg markers were found to co-localize with Hassal’s corpuscles and activated DCs, supporting 
a role for this structure in human Treg development (Watanabe et al., 2005). 
1.2.2.2 Role of cytokines in regulatory T cell development 
Both in the thymus and the periphery it is clear that the cytokine environment plays a crucial 
role for Treg development, as demonstrated by the complete abrogation of Treg development 
in mice missing the common γ-chain, involved in the signaling of several cytokines such as IL-
2, IL-7 and IL-15 (Fontenot et al., 2005b). IL-2 signaling in particular has been shown to induce 
Foxp3 expression, and IL-2 deficient mice or mice missing IL-2 downstream signaling 
molecules display reduced Foxp3 Treg populations in the thymus and the periphery (Fontenot 
et al., 2005b; Turka and Walsh, 2008). However, Foxp3+ Tregs do develop in the thymus 
despite the lack of IL-2 or CD25, and thus it appears that other cytokines signaling through the 
common γ-chain may play complimentary roles to IL-2 during thymic development. 
TGF-β is another cytokine that has been implicated in Treg development, and shown to be 
important for the peripheral induction and maintenance of Foxp3+ Treg in mice (Marie et al., 
2005). However, its contribution to the thymic development of Treg has been debated, and it 
appears that TGF-β signaling contributes to, but is not absolutely essential for thymic Treg 
induction (Liu et al., 2008; Marie et al., 2005). Interestingly, the downstream transcription 
factor of TGF-β, mothers against decapentaplegic homolog 3 (SMAD3) has been demonstrated 
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to bind a conserved enhancer region within the Foxp3 gene together with nuclear factor of 
activated T cells (NFAT) thus promoting Foxp3 transcription (Tone et al., 2008). 
1.2.2.3 Functional Treg subsets 
The functional and phenotypical heterogeneity of the human CD4+FOXP3+ Treg population is 
well-established (Sakaguchi et al., 2010). Many markers have been suggested to delineate 
different functional Treg subsets, where one of the most established ones is the naïve and 
memory T lymphocyte markers, CD45RA and CD45RO respectively (Miyara et al., 2009; 
Valmori et al., 2005). The CD45RA+CD45RO- Treg population, also referred to as naïve or 
resting Tregs, do not express the proliferation marker Ki-67 ex vivo, but readily proliferate, 
exert suppressive function and convert to CD45RO+ cells upon TCR stimulation (Miyara et al., 
2009). This resting human Treg subset is most pronounced in young individuals, decreases 
with age and has been shown to be relatively resistant to activation induced apoptosis by 
CD95/CD95L (Fas/FasL) interactions (Fritzsching et al., 2006; Valmori et al., 2005). In 
contrast, the majority of FOXP3+ CD4+ Treg cells in adults expresses CD45RO ex vivo, a 
population characterized by rapid turnover (Vukmanovic-Stejic et al., 2006), that is 
functionally suppressive but sensitive to activation induced cell death (Fritzsching et al., 2005; 
Miyara et al., 2009). The high expression of many markers associated to T lymphocyte 
activation, such as CD25, CTLA-4 and CD95, within this population makes it difficult to 
discriminate from activated memory-type T lymphocytes. Interestingly, the level of CD25 and 
FOXP3 expression seems to delineate two different CD45RO+ populations, where the 
CD25highFOXP3high cells exhibit greater suppressive function and are less prone to pro-
inflammatory cytokine production compared to CD45RO+ cells with lower CD25 and FOXP3 
expression (Miyara et al., 2009). These CD45RO+FOXP3low cells presumably represent, or are 
at least contaminated by, activated conventional T lymphocytes with an induced transient 
expression of FOXP3, as demonstrated by the higher methylation status of the FOXP3 
promoter and CNS2 region in this population (Miyara et al., 2009). 
In humans, expression of the MHC II molecule HLA-DR also defines a functionally distinct 
Treg population, where HLA-DR+ Treg display faster and more potent suppressive responses 
than their HLA-DR- counterparts (Baecher-Allan et al., 2006). Like conventional T 
lymphocytes, HLA-DR- Treg have been demonstrated to upregulate HLA-DR upon activation, 
however the Treg population appears to stay HLA-DR+, in contrast to conventional T 
lymphocytes that only transiently express HLA-DR after stimulation (Baecher-Allan et al., 
2006). Thus, it has been proposed that these HLA-DR+ Treg represent a terminal effector Treg 
subpopulation in humans (Sakaguchi et al., 2010).  
1.2.3 Regulatory T cell stability and plasticity 
Epigenetic control is a well-established means of gene regulation within the immune system, 
and mechanisms such as histone modifications and DNA methylation carefully govern cell fate 
decisions in developing lymphocytes (Wilson et al., 2005). The uncertain ontogeny of 
peripheral CD4+FOXP3+ Tregs, fueled the search for markers that distinguish cells committed 
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to the Treg lineage from those with only transient FOXP3 expression. Recent years have started 
to illuminate the underlying epigenetic mechanisms that facilitate FOXP3 expression and thus 
deepened our understanding of the molecular background to a stable Treg lineage. 
Mantel and colleagues first described the FOXP3 promoter region and demonstrated it to be 
accessible for the transcription machinery in both CD4+CD25high and CD4+CD25low T cells 
(Mantel et al., 2006). It was also found to contain binding sites for nuclear factor of activated 
T cells (NFAT) and activator protein 1 (AP-1), transcription factors which are well-established 
mediators of T cell activation, in agreement with the possibility of FOXP3 transcription in 
activated CD4+CD25low T cells (Mantel et al., 2006). In 2006, IL-2 was shown to induce 
FOXP3 expression in human Natural Killer (NK) cells treated with 5-aza-2'-deoxycytidine, 
indicating that DNA methylation could be important in the transcriptional control of this gene 
(Zorn et al., 2006). Indeed, studies by our as well as other research groups soon reported a Treg 
specific methylation pattern in the FOXP3 gene (paper I, and (Baron et al., 2007; Floess et al., 
2007)). Over the years since, a constantly increasing amount of data has further emphasized 
the importance of the epigenetic landscape for the stable commitment to the Treg cell lineage, 
and a number of so called Treg-specific demethylated regions (TSDRs) have been defined in 
different genes throughout the genome (Morikawa and Sakaguchi, 2014). 
To date, four different conserved regulatory elements within the Foxp3 gene have been 
described; the promoter region and conserved non-coding DNA sequences (CNS) 1-3 (Baron 
et al., 2007; Floess et al., 2007; Janson et al., 2008; Zheng et al., 2010). During the course of 
tTreg development in mice, it appears that the epigenetic signature of Tregs is actively 
imprinted by DNA demethylation starting at the CD4SP stage in the thymus (Toker et al., 
2013). Interestingly, paralleling the largely Foxp3 independent Treg expression profile in mice 
discussed previously, induction of a Treg specific hypomethylation pattern (of Foxp3 and other 
Treg associated genes such as Ctla4 and Il2ra (CD25)) is largely unaffected by the absence of 
functional Foxp3 (Ohkura et al., 2012). Thus, it seems that Foxp3 itself is essential in the 
execution of the Treg suppressive phenotype and perhaps not so involved in the initial induction 
of the Treg lineage (Miyao et al., 2012; Ohkura et al., 2012; Samstein et al., 2012). 
Establishment of the epigenetic signature of the committed Treg population enables the 
distinction of uncommitted, transiently FOXP3 expressing cells. This is extremely important 
especially for the distinction of committed Treg populations in inflammatory settings, as well 
as for the establishment of future immunotherapies attempting to boost or target the Treg 
lineage. However, some caution is warranted when attempting to extrapolate mouse data to the 
human setting. This also applies to FOXP3 and its regulation, since the expression pattern of 
this gene differs between humans and mice, and the epigenetic regulation of other 
inflammatory genes such as Ifng have been shown to be differentially regulated between these 
two species (Janson et al., 2009). 
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1.2.4 Regulatory T cell effector mechanisms 
Multiple mechanisms have been proposed for how Tregs exert their suppression on other 
immune cells including both cell contact dependent and independent modes of action. In vitro 
studies have shown that Tregs require both antigen specific TCR stimulation and co-
stimulation to exert suppression, however, once activated the Treg population is non-specific 
in its suppression (Sakaguchi, 2004). 
Figure 3 summarizes major Treg suppressive mechanisms. The secretion of soluble inhibitory 
factors such as TGF-β, IL-10 and IL-35 can inhibit the local immune response by acting on 
target cells such as APCs or T cells, and represent a cell-cell contact independent effector 
mechanism (although both secreted and membrane bound forms of TGF- β have been 
described) (Schmitt and Williams, 2013; Toda and Piccirillo, 2006). By comparison, cell 
contact mediated effector mechanisms include surface expression of inhibitory molecules such 
as CTLA-4 (described above), and LAG-3, a homologue to the TCR co-receptor CD4 that can 
suppress DC maturation upon interaction with MHC II molecules on these cells (Liang et al., 
2008). As mentioned previously, CTLA-4 binds B7 co-stimulatory molecules with higher 
affinity than CD28 and can thus potentially both block co-stimulation at the same time as it 
sends negative regulatory signals to the APC (Murakami and Riella, 2014). Moreover, CTLA-
4 interactions with APCs has been demonstrated to induce secretion of IDO, an enzyme that 
catalyzes the local breakdown of tryptophan resulting in metabolic disruption and suppression 
of T lymphocyte responses (Munn et al., 1999). 
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In addition, several distinct mechanisms have been described whereby Tregs can inhibit T 
lymphocytes through the elevation of intracellular cAMP levels in the responder cells. Firstly, 
Tregs can induce a local anti-inflammatory environment by the production of pericellular 
adenosine generated from ATP by CD39 (nucleoside triphosphate diphosphohydralase-1 
(NTPDase1)) on the Treg cell surface and CD73 (ecto-5’-nucleotidase) on Tregs or other cells 
in the local environment (Antonioli et al., 2013b). The adenosine signaling system is complex 
and has several implications in immune regulation (see also section 1.3). Local adenosine 
production limits T lymphocyte immune responses primarily through engagement of the 
adenosine A2A receptors that leads to increased cAMP levels in the target cells (Ohta and 
Sitkovsky, 2001). Moreover, human iTreg have been shown to express cyclooxygenase-2 
(COX-2) that result in prostaglandin E2 production dependent elevation of intracellular cAMP 
and suppression of immune responses (Mahic et al., 2006). Strikingly, Treg have also been 
described to suppress responder cells by direct transfer of cAMP through gap junctions (Bopp 
et al., 2007). 
FOXP3 in itself has been shown to repress IL-2 expression, coherent with the fact that FOXP3+ 
Treg do not express this cytokine (Schubert et al., 2001). They are however, inherently 
dependent on IL-2 signaling for survival and maintenance (Maloy and Powrie, 2005) and given 
their constitutively high expression of CD25, the local consumption of IL-2 depriving other T 
lymphocyte subsets of this growth factor, has been suggested as a contributing effector 
mechanism (Pandiyan et al., 2007). 
Finally, Tregs have also been demonstrated to directly kill their target cells by a variety of 
mechanisms involving either apoptosis inducing ligands such as FasL (Janssens et al., 2003) 
or granzyme/perforin secretion (Grossman et al., 2004a; Grossman et al., 2004b). Taken 
together, the above mechanisms most probably represent complimentary pathways utilized by 
Treg populations under different conditions to control immune responses, and mirror the 
complexity of the Treg phenotypes described in various contexts. 
1.3 ADENOSINE RECEPTOR SIGNALING 
The purine adenosine is ubiquitously present throughout the body as an important player in cell 
metabolism. Its extracellular concentration is highly dependent on the metabolic state of the 
tissues and influenced by various stimuli such as stress, hypoxia and inflammation (Fredholm, 
2007). The importance of adenosine receptor signaling has been demonstrated in multiple both 
physiological and pathological contexts ranging from cardiovascular effects and temperature 
regulation to cell differentiation, migration and immune regulation (Fredholm, 2007). 
Adenosine signals through four 7-transmembrane G-protein coupled receptors namely the 
adenosine A1, A2A, A2B and A3 receptors (A1R, A2AR, A2BR and A3R) (Figure 4). The A2AR 
and A2BR signal predominantly through Gs whereas the A1R and A3R couple predominantly 
to Gi proteins thus resulting in elevated or decreased intracellular cAMP levels respectively 
(Fredholm et al., 2011). In addition, all four receptors have been shown to affect MAPK 
signaling pathways, including extracellular signal activated kinase 1 (ERK1), ERK2, p38, and 
c-jun N-terminal kinase (JNK) (Schulte and Fredholm, 2003b). In terms of adenosine 
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concentrations required for signaling, A1, A3 and A2ARs are thought to be able to signal already 
at physiological concentrations, whereas A2BRs require higher adenosine levels to induce 
intracellular changes in cAMP level (Fredholm, 2007). In contrast, A2BRs have been shown to 
have the lowest threshold for MAPK signaling, suggesting that this pathway may be the major 
contributor to A2BR mediated effects under physiological conditions (Schulte and Fredholm, 
2000). 
In the immune system, the immunosuppressive effects of the A2AR are well-established. The 
A2AR is expressed on immune cells from both myeloid and lymphoid lineages and its 
importance in immune regulation is demonstrated by the exaggerated inflammation displayed 
by A2AR-/- mice (Ohta and Sitkovsky, 2001; Ohta and Sitkovsky, 2014). Interestingly, also 
A2BR-/- mice display a dysregulated immune response, and these findings are mirrored in 
murine tumor models by a lower susceptibility to tumors in both A2AR-/- and A2BR-/- mice (Ohta 
et al., 2006; Ryzhov et al., 2008). Activation of A2ARs on the different immune subsets has 
been shown to inhibit T and NK lymphocyte responses, and A2BR signaling promotes 
alternative activation of APCs (Antonioli et al., 2013a). Furthermore, it appears that adenosine 
signaling also plays a role in T lymphocyte homeostasis and differentiation, where A2AR 
stimulation is involved in maintenance of peripheral T lymphocytes (Cekic et al., 2013), and 
both A2AR and A2BR stimulation have been implied in Treg induction in mice (Ehrentraut et 
al., 2012; Ohta et al., 2012). 
Although the A2ARs are most abundantly expressed by T lymphocytes and the most well-
studied of the adenosine receptors in this cell type, expression of all four receptors have been 
reported on conventional T lymphocytes as well as Tregs (Cekic et al., 2013; Ehrentraut et al., 
2012). Still, the function of A1R and A3Rs in the immune system has mostly been studied in 
myeloid derived cell types, where adenosine signaling has been linked to diverse functions 
such as degranulation, adhesion, migration and antigen presentation (Burnstock and 
Boeynaems, 2014).  
  
 
Figure 4. The four types of adenosine receptors: A1, A2A, A2B and A3 receptors, and the 
preferentially associated G-protein to each receptor. 
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1.4 THE CONCEPT OF CANCER 
Cancer as a disease has captivated the scientific community for generations. Intense research 
has resulted in a deepened understanding of the traits that characterize human malignancies, 
first summarized by Hanahan and Weinberg in 2000 (Hanahan and Weinberg, 2000). Their 
theory stipulates six basic hallmarks of cancer that are acquired during the multistep 
progression of human tumors, namely: (1) Independence from exogenous growth signals, (2) 
resistance to antigrowth signals as well as (3) apoptosis, (4) limitless proliferative ability, (5) 
angiogenesis induction and (6) invasion/metastasis capability (Hanahan and Weinberg, 2000). 
The multistep cancer evolution theory is supported by pathological data from several tumors 
where an evolution from premalignant lesions to invasive tumors is observed (Foulds, 1954). 
In addition, the theory is further strengthened by epidemiological evidence from solid tumors, 
such as e.g. bladder cancer, with an age related incidence where between seven and eight 
separate evolutionary events have been inferred (Renan, 1993). These tumor specific changes 
are acquired through a variety of different molecular changes, enabled by genetic instability 
and DNA mutations in the tumor cells. Consequently, throughout the process of tumor 
development, tumor cells acquire a protein signature that separates them from their normal 
tissue progenitors. Such foreign proteins can potentially elicit an anti-tumor immune response 
by which the body is able to recognize and eliminate altered cells. The field of tumor 
immunology has vastly expanded over the past decades, and in a recent update of the Hallmarks 
of Cancer theorem, tumor immune evasion is now included as an emerging hallmark (Hanahan 
and Weinberg, 2011).  
In the context of tumor development however, it is interesting to note the ambiguous role that 
inflammation plays where the inflammatory process as such has been shown to promote tumor 
progression in many tumors (de Visser et al., 2006). Indeed, inflammation facilitates most if 
not all of the basic characteristics of cancers, and epidemiological data link chronic 
inflammatory conditions to the development of different kinds of tumors in humans (Elinav et 
al., 2013; Hanahan and Weinberg, 2011). Myeloid cells of the innate immune system have been 
widely implied in promotion of tumor progression through mechanisms such as production of 
reactive oxygen species, metalloproteinases, a diverse palette of chemokines and cytokines as 
well as suppression of adaptive immune responses (de Visser et al., 2006; Elinav et al., 2013; 
Gabrilovich et al., 2001). Of note, even though lymphocyte infiltration is a positive prognostic 
indicator in many tumors (Galon et al., 2006; Lipponen et al., 1992; Zhang et al., 2003) and 
adoptive immunotherapy of expanded T cells has proven promise in the clinical treatment of 
patients (Dudley et al., 2005; Karlsson et al., 2010), the adaptive immune system has also been 
implied to promote tumor progression under certain circumstances (Alizadeh et al., 2013; 
DeNardo et al., 2009). In summary, it appears the range of immune effects on tumors can span 
from tumor cell elimination to promotion of tumor growth and invasion. Understanding the 
cellular and molecular pathways that shift the response in either direction will help us exploit 
these mechanisms in the design of future immunotherapies of cancer. 
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1.5 TUMOR IMMUNITY 
Cancer immune surveillance – the idea that cells of the immune system continuously circulates, 
monitors and protects the body from developing cancers – as a means to eliminate tumors is 
now widely accepted (Dunn et al., 2004). Studies on IFN-γ and perforin in mice revealed the 
importance of these key immunological substances to prevent the development of both 
spontaneous and chemically induced tumors, providing a basic proof for the hypothesis of 
tumor immune surveillance (Shankaran et al., 2001; Street et al., 2001). In humans, tumors are 
often infiltrated by T lymphocytes, the presence of which correlates positively to disease 
outcome (Galon et al., 2006; Lipponen et al., 1992; Zhang et al., 2003), and tumor antigen-
specific functional T lymphocytes have been observed in human cancer patients (Guckel et al., 
2006). The concept of immunoediting and its “three E’s” comprises: 1) Elimination, which 
basically encompasses the concept of immune surveillance, 2) equilibrium, a process where 
the immune system interacts with the tumor, contributes to the evolutionary selection of tumor 
cell clones and may serve to “edit” the tumor phenotype, and finally, 3) escape, where tumor 
cells manage to evade the immune system and grow in otherwise apparently immunocompetent 
hosts (Dunn et al., 2004). 
1.5.1 Immune escape 
Tumor immune escape encompasses multiple mechanisms by which tumors manage to elude 
the immune system and involves diverse immune cell types. T lymphocyte responses are 
evaded mainly by avoiding recognition or by disabling the effector T cells (Teff), each of which 
is executed through a number of different mechanisms, including induction of tolerance, altered 
antigen presentation, immunosuppressive microenvironment, co-inhibition, and/or 
involvement of regulatory cell populations (Rabinovich et al., 2007). 
1.5.1.1 Induction of tolerance 
A major obstacle in mounting an immune response against tumors is that not all tumor antigens 
are tumor specific, i.e. some are also expressed by normal tissues. Thus the immune system 
may fail to recognize the cancer as foreign and be rendered unresponsive, which has indeed 
been shown in both CD4+ and CD8+ T lymphocyte populations (Lee et al., 1999; Rabinovich 
et al., 2007; Staveley-O'Carroll et al., 1998). 
A major mechanism of tolerance induction is mediated through APCs, where especially 
dendritic cells, play a central role in the development of immune responses against cancer, but 
also contribute to the control of immune responses (Rabinovich et al., 2007; Steinman et al., 
2003). DC antigen capture and presentation of antigen in the absence of an inflammatory 
environment fails to trigger DC maturation and expression of co-stimulatory molecules, 
rendering the DCs incapable of eliciting a robust antigen-specific response. Studies of cancer 
patients revealed decreased numbers of differentiated DCs, but an accumulation of immature 
DCs with reduced capacity to activate T cells (Pinzon-Charry et al., 2005). Many different 
pathways have been implicated by which DCs may suppress anti-tumor immune responses (Ma 
et al., 2012). Such mechanisms include expression of IDO (Munn et al., 2004) and arginase 
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(Liu et al., 2009), secretion of immunoregulatory cytokines (Shurin et al., 2013) and expression 
of inhibitory molecules such as programmed death ligand 1 (PD-L1) (Mu et al., 2011). Thus 
DCs are very much implied in tumor escape mechanisms, however, a more in-depth description 
of DC subtypes and their involvement in tumor escape are beyond the scope of this text. 
1.5.1.2 Altered antigen presentation 
Genetic instability is a hallmark trait of cancer cells (Hanahan and Weinberg, 2011), and forms 
the basis for the production of cancer-specific antigens that the body can recognize as foreign. 
How then, is it that tumor cells manage to hide these changes from the immune system? One 
classical way of tumor immune evasion is the defective presentation of antigens through the 
MHC I pathway. Downregulation of MHC I expression has been observed in many forms of 
human cancers, where the most common mechanism for total loss of expression is mutations 
in or deletion of the ß2-microglobulin genes (Hicklin et al., 1999; Rabinovich et al., 2007). 
Alternatively, a variety of different mechanisms can work to downregulate the transcription of 
MHC I genes, or affect the antigen processing through the transporter associated with antigen 
processing (TAP) and to some extent proteosomal subunits low molecular mass polypeptide 
(LMP) 2 and 7 (Hicklin et al., 1999). 
1.5.1.3 Importance of the tumor microenvironment 
The tumor microenvironment and its molecular interactions between the tumor and immune as 
well as other cells in the tumor stroma are central in both development and progression of 
tumors. Of note, chronic inflammation in tumor tissue sometimes not only fails to elicit an 
adequate response but can also promote cancer development (de Visser et al., 2006). Tumors 
release inhibitory factors that affect both the innate and the adaptive immune system, recruit 
stromal cells and regulatory cell populations such as Tregs and myeloid derived suppressor 
cells that during recent years have been attributed increasing importance in the development 
and progression of solid tumors (Hanahan and Weinberg, 2011). 
The enzyme IDO (discussed briefly in previous sections) is one mediator of T cell suppression 
that has been linked to cancer, where it can be expressed not only by immune cell populations 
but also by the tumor itself (Uyttenhove et al., 2003). IDO catalyzes the rate-limiting step in 
the degradation of the amino acid tryptophan, and is expressed by a variety of cell types in 
response to inflammatory signals, within the immune system normally by APCs in response to 
external stimuli (Munn et al., 1999). The depletion of tryptophan and the generation of 
immunosuppressive metabolites, result in direct T cell suppression as well as enhancement of 
local Treg function (Munn and Mellor, 2007). IDO expression has been observed in human 
tumors as well as tumor-draining lymph nodes, and is associated with poor prognosis 
(Brandacher et al., 2006; Ino et al., 2006; Munn et al., 2004; Okamoto et al., 2005). 
Many cytokines have been implicated in tumor immune suppression, of which TGF-ß is one 
of the most prominent. This cytokine has a dual role in cancer development as it inhibits 
proliferation of normal cells, but its expression is associated with immunosuppression in 
cancers; TGF-ß promotes the generation and maintenance of Tregs, but can also directly 
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suppress T and NK cell anti-tumor immune responses (Wan and Flavell, 2007). Besides TGF-
ß, several other suspected microenvironmental molecular culprits have been implicated in 
tumor immune escape, including IL-10 and prostaglandin E2 (Rabinovich et al., 2007). 
Moreover, the relatively hypoxic environment within the tumor can in itself suppress immune 
responses, e.g. through the accumulation of local adenosine. The recruitment of activated Tregs 
to the tumor tissue can further increase adenosine levels through the action of the membrane 
bound enzymes CD39 and CD73 as discussed previously, and contribute to immune 
suppression by adenosine receptor signaling (Antonioli et al., 2013b). Interestingly, many 
tumors have also been shown to express these enzymes (Antonioli et al., 2013b; Bastid et al., 
2013), which have been linked to higher stage tumors and poor prognosis (Kunzli et al., 2011; 
Stella et al., 2010). Furthermore, the metabolism of ATP to adenosine may also contribute to 
tumor immune escape by the decreased engagement of ATP receptors such as P2Y2 and P2RX7 
on APCs and thereby reducing the activation of these cells (Bastid et al., 2013). 
Yet another way to achieve immunosuppression is through the engagement of negative co-
stimulatory pathways. CTLA-4, discussed previously, is one such molecule that can be 
expressed by tumor cells and has been shown to induce apoptosis in target cells (Contardi et 
al., 2005). Furthermore, the interactions of programmed death receptor 1 (PD-1) and 
programmed death receptor ligand 1 (PD-L1) have also been implied in this context, where 
PD-L1 expression on tumor cells show a strong inverse correlation to patient survival (Blank 
and Mackensen, 2007). Of note, the importance of these pathways has been emphasized during 
recent years with the successful development of immunotherapies such as ipilimumab and 
Nivolumab, targeting CTLA-4 and PD-1/PD-L1 pathways respectively (Hodi et al., 2010; 
Philips and Atkins, 2015). 
1.5.1.4 Regulatory T cells and FOXP3 in human cancers 
The induction and/or recruitment of CD4+ Tregs by tumors represent a possible means of tumor 
immune escape. In concordance with this hypothesis CD4+ Tregs have been observed to 
increase in the peripheral blood of patients with several types of cancers, and accumulate in 
tumor tissue and draining lymph nodes (Nishikawa and Sakaguchi, 2010). It is at present 
unclear whether these cells represent a non-specific increase in the Treg pool, expansion of 
tumor-specific tTreg or pTreg cells, although antigen-specific Treg clones have been described 
(Wang et al., 2004). Interestingly, cancer resection has been reported to normalize the elevated 
Treg levels, indicating that the increase of the Treg population is indeed caused by the cancer 
(Kono et al., 2006). In tumor draining lymph nodes, one study demonstrated increasing 
numbers of Tregs the closer the proximity of the tumor (Kawaida et al., 2005). Intratumoral 
localization of FOXP3+ Tregs has also been shown in several tumor types, but whether these 
cells are activated T helper cells with transiently induced FOXP3 expression or committed Treg 
remains to be determined (Adeegbe and Nishikawa, 2013). Indeed the known heterogeneity of 
human Treg populations is mirrored by the clinical prognostic implications of tumor infiltrating 
FOXP3+ Tregs, which range from poor to good in a wide collection of studies in different 
human tumors (reviewed by (deLeeuw et al., 2012)). For example, Curiel and colleagues 
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demonstrated that ovarian tumor infiltrating Tregs were linked directly to reduced survival, and 
also illustrated that the chemokine CCL22 secreted by ovarian tumors was responsible for Treg 
recruitment through the interaction with CCR4 on these cells (Curiel et al., 2004). In contrast, 
the presence of tumor infiltrating FOXP3+ cells is associated to improved survival in other 
types of cancer such as colorectal cancer (Salama et al., 2009) and as we have shown urinary 
bladder cancer (Winerdal et al., 2011). Studies have even reached opposite conclusions 
regarding the same cancer location; as different papers have reported good, neutral or poor 
prognostic claim for FOXP3+ TILs in e.g. oral and gastric cancer, and this general diversity 
appeared independent of antibody clone used or quantification method (deLeeuw et al., 2012). 
The molecular subtype of tumor could possibly contribute to this diversity, as exemplified by 
breast cancer where the prognostic significance of FOXP3+ TIL differs between estrogen 
receptor positive and negative tumors (Mahmoud et al., 2011). It would thus seem that both 
location and type of tumor influences the clinical impact of FOXP3+ TIL. 
Interestingly, recent studies have shown that tumors can also express FOXP3 (Hinz et al., 2007; 
Karanikas et al., 2008). This expression correlated to IL-10 and TGF-β (Karanikas et al., 2008), 
and co-culture of naïve T cells with FOXP3-expressing tumor cells from pancreatic carcinoma 
inhibited T cell proliferation (Hinz et al., 2007). Interestingly, although FOXP3 has been shown 
to function as a tumor suppressor in vitro e.g. by the repression of c-Myc expression (Wang et 
al., 2009), it is generally associated to bad clinical prognosis and higher risk of metastasis 
(Triulzi et al., 2013). Different models have been proposed to explain this apparent 
discrepancy: Tumor related mutations within the FOXP3 protein could abrogate the tumor 
suppressor effect, FOXP3 could play a dual role by limiting proliferation but supporting tumor 
progression, or FOXP3 expression could putatively bestow the tumor with immunoregulatory 
properties, fostering immune escape (Triulzi et al., 2013). Of note, at least the first and last of 
these alternatives are not mutually exclusive. In conclusion, it appears that FOXP3 is involved 
on more than one side in tumor-immune interactions, and still much remains to be elucidated 
regarding its biological implications. 
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2 AIMS OF THE THESIS 
The overall aim of this thesis was to study regulatory T cells in both the physiological context 
and the pathological cancer setting, in order to better understand their natural characteristics, 
illuminate their impact disease progression and find potential ways to target them in 
immunotherapy. The specific aims of each paper were: 
Paper I. To map the relationship of FOXP3 promoter methylation and FOXP3 expression in 
Treg and conventional CD4+ T helper lymphocytes in order to assess whether this may be used 
as a marker of committed human Tregs. 
Paper II. To investigate the impact of CD3+ and FOXP3+ tumor infiltrating lymphocytes as 
well as tumor FOXP3 expression on survival in urinary bladder cancer. 
Paper III. To examine how the T lymphocyte responses vary with tissue location and with 
therapy in patients with urinary bladder cancer. 
Paper IV. To study the impact of adenosine receptor signaling on T lymphocyte development 
in general and Treg development in particular in adenosine receptor knockout mice. 
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3 MATERIALS AND METHODS 
Here follows a summary of the materials and methods used. For more detailed descriptions, 
please refer to the respective papers (I-IV). 
3.1 PATIENTS 
3.1.1 Patient characteristics (Paper I-III) 
In paper I, only buffy coats from male healthy blood donors were used in the methylation 
analyses to avoid the risk of artefacts due to random X-chromosome inactivation in women. 
Paper II and III both encompass urinary bladder cancer (UBC) patients. Paper II is a 
retrospective study of 37 UBC patients with muscle invasive disease that underwent radical 
cystectomy at Karolinska University Hospital between the years 1999-2002. The mean age of 
the included patients was 67 (median 69, range 46-81) at the time of the diagnostic TUR-B and 
11 out of 37 patients in this study were female. At the time, neoadjuvant chemotherapy was not 
routinely given to this group of patients, however, 10 of the patients received postoperative 
chemotherapy, a fact which was accounted for in the study analyses. 
In comparison, paper III is a prospective study of 32 UBC patients with suspected muscle 
invasive disease at the time of inclusion at one of the collaborating study centers (Umeå 
University Hospital, Sundsvall-Härnösand County hospital, Gävle Hospital, Falun Central 
Hospital, Enköping Hospital and Uppsala University Hospital) 2013-2014. The mean age of 
the included patients in this study was 69.2 years (median 70, range 55-87) and 10 out of 32 
patients were female. 7 out of the 15 patients that underwent cystectomy received neoadjuvant 
chemotherapy prior to cystectomy according to the MVAC (Methotrexate, Vinblastine, 
Adriamycin and Cisplatinum) routine. 
3.1.2 Sentinel node detection and surgical methods 
In study III, patient tissue samples were received both at the initial transurethral resection of 
the bladder (TUR-B) and at cystectomy. At the TUR-B, peripheral blood and cold-cup biopsies 
from macroscopically healthy bladder tissue were received in addition to tumor samples. 
Whenever possible, separate tumor fractions were taken from the central part (CP), transitional 
zone (TZ) and invasive front (IF) of the tumor. At cystectomy, sentinel node detection was 
carried out preoperatively as previously described (Sherif et al., 2001) by transurethral injection 
of the radioactive tracer Nanocoll® around the edge of the tumor area, and sentinel nodes (SNs) 
were identified after excision of the main specimen both in vivo and ex vivo. An example of a 
lymph node map from a cystectomized patient in the study is shown in Figure 5. In addition to 
the tumor-draining sentinel lymph nodes (SNs), non-draining lymph nodes (nSNs), peripheral 
blood, tumor and macroscopically healthy bladder tissue samples were collected at the time of 
cystectomy whenever possible.  
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3.1.3 Patient follow-up 
In the retrospective study II, primary and secondary endpoints were overall survival and 
progression-free survival respectively, where disease progression was defined as local 
recurrence, appearance of distant metastases or pathologically enlarged lymph nodes in patients 
that had been regarded as free of disease after cystectomy. The prospective design of study III 
in combination with the relatively short follow-up time of the patients included, limits the 
interpretability of any results based on the clinical follow-up parameters at this stage. Therefore 
the results in this paper are based solely on the clinical parameters at the time of surgery and 
do not take follow-up into account. 
3.2 MICE (PAPER IV) 
Five separate mouse genotypes were studied in paper IV: In addition to wild type C57BL/6 
(WT), adenosine A1 receptor knock-out (Johansson et al., 2001), adenosine A2A receptor 
knock-out (Chen et al., 1999), adenosine A2B receptor knock-out (Csoka et al., 2007) and 
adenosine A3 receptor knock-out (Salvatore et al., 2000) animals, all on C57BL/6 background 
were used. All experiments were approved by Stockholms Norra Djurförsöksetiska Nämnd and 
carried out in accordance with local institutional guidelines. 
3.3 CELL PREPARATION AND CULTURE (PAPER I, III AND IV) 
In the human studies, peripheral blood mononuclear cells (PBMCs) were isolated from buffy 
coats (paper I) or heparinized peripheral blood (paper III) by density gradient centrifugation 
(Ficoll-Paque PLUS, Amersham Biosciences). Tissue infiltrating immune cells from tumor and 
macroscopically healthy bladder tissue were extracted with a GentleMACS homogenizer in 
AIM-V medium (Gibco, Life technologies) containing Collagenase/Hyaluronidase (StemCell 
Figure 5. (A) Detection map from a cystectomy in the study. Numbers indicate different 
specimens: 1: The bladder. 2-4, 7, 8: Sentinel nodes. 9, 11: Non Sentinel nodes. (B) Schematic 
image of the different tumor sublocations investigated in the study. CP = Central Part, TZ = 
Transitional Zone, IF = Invasive Front 
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Technologies). Lymph node leukocytes were extracted by gentle homogenization through a 
40µm cell strainer in AIM-V medium. Murine cells from thymi, lymph nodes and spleens were 
extracted by gentle homogenization and filtration through a 70µm cell strainer. 
Magnetic cell sorting (MACS) in combination sorting of immune cell subpopulations on a 
FACS Aria Cell sorter was used to isolate lymphocyte populations of interest (paper I and III). 
All sorted cell populations were confirmed >95% pure by FACS. 
In paper I, cells were cultured in AIM-V or RPMI 1640 supplemented with 10% human serum, 
180U rIL-2, 100µg/mL streptomycin, 100U/mL penicillin and 2mM L-glutamine (all additives 
from Sigma) and anti-CD3/CD28 Dynabeads (Invitrogen) or anti-CD3 and anti-CD28 
antibodies were used to stimulate the cells. In paper III, AIM-V alone was used as culture 
medium, only L-glutamine was added, and cells were stimulated with tumor extract as 
described previously (Marits et al., 2006). 
3.4 IMMUNOLOGICAL EVALUATION 
3.4.1 Flow cytometry (Paper I, III and IV) 
For surface staining, leukocyte cell populations of interest were labelled with antibodies as 
indicated in the respective materials and methods section of paper I, III and IV. Intracellular 
staining for FOXP3 (paper I and III) or Foxp3 and Helios (paper IV) was performed using the 
Foxp3 staining buffer set from eBioscience according to the manufacturer’s protocol. 
Acquisition of flow cytometry data was performed on a FACSCalibur or FACSAria (paper I) 
alternatively an LSRForstessa II (paper III and IV) (all from BD Biosciences). Data analysis 
was performed with Cell Quest Pro or FACSDiva (paper I) or FlowJo X 10.0.7r2 (paper III 
and IV) software. 
3.4.2 Functional T lymphocyte assays (Paper I and III) 
3.4.2.1 Proliferation assays (Paper I) 
The suppressive capacity of isolated Treg populations was assessed by co-culture with 
CD4+CD25- responder cells at Treg:Tresponder ratio 1:1-1:4. The cells were stimulated with 
plate bound anti-CD3 and soluble anti-CD28 antibodies and proliferation evaluated by 
[3H]Thymidine incorporation after 4-5 days of culture. Alternatively, proliferation was 
evaluated by dilution of carboxyfluorescein succinimidyl ester (CFSE) staining in the 
responder population. 
3.4.2.2 Flow cytometric assay of cell mediated immune response in activated lymphocytes 
(Paper III) 
In order to assess the responsiveness of cells isolated from the different locations to tumor 
antigens, 5x105 cells from peripheral blood or lymph nodes were cultured in U-bottomed 96-
well plates with tumor homogenate prepared as described in paper III. As control for tumor 
specific reactivity macroscopically healthy bladder tissue homogenate was used, and in 
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addition 5µg/mL of pokeweed mitogen or medium only were included as positive and negative 
controls respectively. 
3.4.3 Immunohistochemistry (Paper II) 
Serial, 4µm sections of paraffin embedded tumor samples were mounted on glass slides and 
incubated at 60ºC for 1h before the sections were deparaffinized in xylene and subsequently 
rehydrated in an ethanol dilution series. Heat induced epitope retrieval was performed in a 
microwave oven in Citrate buffer pH 6.0 (for CD3 staining) or Tris-EDTA buffer pH 9.0 (for 
FOXP3) for 20 min. Blocking was performed with diluted serum from the host species of the 
secondary antibody (goat). Mouse anti human CD3 antibody (clone PS1; Vector Laboratories, 
dilution 1:200) and mouse anti human FOXP3 (clone 259D; BioLegend, dilution 1:100) were 
used as primary antibodies, diluted in PBS with 1% bovine serum albumin and 0.05% Tween-
20. Subsequently, the VECTASTAIN Elite ABC kit (Vector Laboratories) was used according 
to the manufacturer’s instructions. Biotinylated goat anti-mouse IgG (Vector Laboratories) was 
used as a secondary antibody (dilution 1:200). In parallel, stainings without the primary 
antibody were performed as negative control and sections of human spleen were used as 
positive control. All washing steps were done in PBS with 0.05% Tween-20. Slides were 
developed in 3, 3’ diaminobenzidine solution (Vector Laboratories) and counterstained with 
Mayer’s hematoxylin before mounting in Pertex solution (HistoLab). 
For analysis, three separate photographs of high power fields (X40) of randomly selected tumor 
areas were taken in corresponding areas of consecutive slides for CD3 and FOXP3 stainings 
respectively. The number of CD3+ and FOXP3+ tumor infiltrating lymphocytes (TILs) was 
quantified, and in addition, FOXP3 expression in tumor cells was defined as positive if >25% 
of the tumor cells were positively stained. Immunohistochemical evaluation was performed by 
two independent researchers blinded to clinicopathological data. 
3.4.4 Polymerase chain reaction (PCR) (Paper I) 
For quantitative real time PCR, total RNA was extracted using the RNA Mini kit (Bio-Rad) 
alternatively TRIZOL reagent (Invitrogen) according to the manufacturers’ protocols. 
Conversion to cDNA was performed with the iScript cDNA Synthesis Kit (Bio-Rad). 
Quantitative PCR was performed with iQSYBR Green Supermix (Bio-Rad) on an iCyclerIQ 
Real Time Detection System (Bio-Rad), and data analyzed with iCycler IQ™ Optical System 
Software Version 3.1 (Bio-Rad). The reliability of different commonly used housekeeping 
genes has been questioned, especially with regard to their stability in activated cell populations 
(Bas et al., 2004; Radonic et al., 2004). With this in mind, we chose RNA polymerase II (RPII) 
as a housekeeping gene since it has a documented stability in many cell types including 
lymphocytes (Radonic et al., 2004). Expression levels were normalized to the housekeeping 
gene using the 2-ΔΔCt method (Livak and Schmittgen, 2001). For regular PCR, ThermoPol 
reaction buffer and Taq DNA polymerase (New England Biolabs) were used on a MyCycler 
Thermal Cycler (Bio-Rad). Primers, with sequences specified in paper I, were obtained from 
Cybergene. 
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3.4.5 DNA methylation analysis (Paper I and III) 
3.4.5.1 Bisulphite sequencing (Paper I) 
DNA from sorted cell populations was isolated with the DNeasy Blood & Tisse Kit (QIAGEN), 
and bisulphite conversion of all non-methylated cytosine bases in the DNA to uracil was carried 
out with the EZ DNA Methylation Kit (ZYMO Research) according the manufacturers’ 
protocols. Subsequently, the FOXP3 promoter region was amplified by PCR and the PCR 
product cloned into a pCR®4-TOPO® vector using a TOPO TA Cloning® Kit (Invitrogen). 
DNA from individual bacterial clones was sequenced using the BigDye® Terminator v1.1 
Cycle Sequencing Kit (Applied Biosystems) with T3 and T7 primers according to the 
manufacturer’s instructions, and run on a 310 Genetic Analyzer (Applied Biosystems). 
Sequence data was analyzed with ABI Prism Sequencing Analysis Software 3.7 (Applied 
Biosystems).  
3.4.5.2 Combined bisulphite restriction enzyme analysis (COBRA) (Paper I) 
Bisulphite converted DNA, prepared as described above, was used as template to amplify the 
FOXP3 promoter region with an unconjugated forward primer and a 5’ 6-FAM conjugated 
reverse primer. The PCR product was treated with the restriction enzyme Aci1 in excess, which 
would cleave the PCR product only if the -77 cytosine in the FOXP3 promoter in original 
template was methylated and thus conserved through the bisulphite conversion. The digested 
DNA product was isolated with a phenol-chloroform extraction and run on a 310 Genetic 
Analyzer (Applied Biosystems) where fragment length was analyzed. Gene Scan v3.7 
application software (Applied Biosystems) was used to analyze the data. 
3.4.5.3 Pyrosequencing (Paper III) 
DNA isolation and bisulphite conversion was carried out with the EZ DNA methylation Direct 
kit (Zymo Research). The FOXP3 target sequence was amplified with biotinylated primers 
(Thermo Scientific and Biomers.net) and pyrosequenced on a PSQ96 Pyrosequencer (Qiagen) 
with Pyromark Gold 96Q reagents (Qiagen) and sequence primers. PyroMark CpG Software 
1.0.11 (Qiagen) was used to analyze the resulting data sequences. 
3.5 BONE MARROW TRANSFER EXPERIMENT (PAPER IV) 
Bone marrow cell suspensions in sterile PBS were prepared from donor knockout mice and 
5x106 cells injected in the tail vein of irradiated (900 rad) WT C57BL/6 recipients. Recipient 
mice received prophylactic antibiotics (neomycin sulphate) for two weeks after the transplant. 
Resulting immunophenotypes were evaluated after 8 weeks. 
3.6 STATISTICAL ANALYSIS (PAPER I-IV) 
Categorical data (paper I) was analyzed with Fisher’s exact test. Survival data was related to 
categorical predictor variables with the log-rank test and Cox’s proportional hazards model 
(paper II). Shapiro-Wilk’s test of normality was used to evaluate if a particular data set was 
parametric or not (paper III and IV). For parametric data, two-sided T-test or one-way ANOVA 
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was used, whereas the Mann-Whitney U test or Kruskall-Wallis ANOVA with Dunn’s test was 
used for non-parametric datasets (paper III and IV). Statistical calculations were done in 
Statistica (StatSoft, Inc. (2013). STATISTICA (data analysis software system), version 12. 
www.statsoft.com) or GraphPad Prism (Version 5.04). P-values <0.05 were considered 
significant. 
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4 RESULTS AND DISCUSSION 
4.1 FOXP3 PROMOTER DEMETHYLATION REVEALS THE COMMITTED TREG 
POPULATION IN HUMANS (PAPER I) 
In the years preceding this study, many Treg markers had been suggested, several of them 
useful in an unchallenged setting but less specific in inflammatory environments as they were 
also upregulated in conventional CD4+ T lymphocytes upon activation as discussed in section 
1.2. When FOXP3 was first discovered as the master transcription factor of the Treg lineage it 
was initially considered a specific Treg marker in both mice and humans (Sakaguchi et al., 
2007). However, before long, reports came of transient FOXP3 induction in human activated 
conventional CD4+ T lymphocytes (Walker et al., 2003; Wang et al., 2007) making them 
impossible to distinguish from Treg based on their protein expression alone. This prompted us 
to ask whether Treg may be distinguished from conventional CD4+ T lymphocytes by the 
epigenetic signature of the FOXP3 gene. We identified a CpG rich region within the conserved 
FOXP3 promoter region and hypothesized that differential methylation of these sites may 
account for the differential stability of FOXP3 expression in CD4+ T lymphocytes. 
Human CD4+CD25hi Tregs displayed a demethylated FOXP3 promoter (1.4%±0.95% SEM 
methylated) in contrast to CD4+CD25lo T lymphocytes, which were partially methylated 
(27.9%±7.1%), and to B cells which were fully methylated (93.8%±1.7%). This was in 
concordance with parallel study by Kim et al. describing the methylation status of the murine 
Foxp3 promoter (Kim and Leonard, 2007). In addition, the promoter appears to have a more 
accessible chromatin configuration in Tregs compared to conventional T lymphocytes, as 
indicated by increased histone acetylation in this region (Mantel et al., 2006), further 
strengthening the role of epigenetic control over FOXP3 transcription. 
Furthermore, we examined the methylation status of the FOXP3 promoter in sorted CD25hi and 
CD25lo cell populations during the course of activation of CD4+CD25lo T lymphocytes (Paper 
I, Figure 6A). Interestingly, there was an initial difference in methylation status in the sorted 
populations during early activation, but over time this difference leveled off at approximately 
60% demethylation. One could speculate that the initial difference in methylation between the 
CD25hi and CD25lo populations during activation may reflect a small contaminating resting 
CD45RA+ Treg subset in the starting population. This population has a demethylated FOXP3 
promoter region, lower CD25 and FOXP3 expression, but higher proliferative capacity than 
their CD45RA- Treg counterparts (Miyara et al., 2009; Valmori et al., 2005), and could 
potentially respond faster to activation than conventional CD4+ T lymphocytes completely 
lacking CD25 expression at the start of the culture. At later time points, both the CD25hi and 
the CD25lo population are more likely to consist of cells of mixed origin, possibly explaining 
why the initial difference gradually disappears. Still, the FOXP3 promoter in CD4+CD25hi T 
lymphocytes sorted ex vivo remained demethylated and these cells stayed FOXP3+ throughout 
the culture. In contrast, although a limited decrease in FOXP3 promoter methylation was 
observed in the stimulated CD4+CD25lo T lymphocytes, it remained partially methylated 
corresponding to the transient FOXP3 expression observed in these cells. Of note, murine 
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CD4+CD25- T lymphocytes reportedly increase their promoter methylation upon TCR 
stimulation in the absence of exogenous TGF-β, possibly preventing the induction of Foxp3 
expression in these cells (Kim and Leonard, 2007), and potentially contributing to the 
differences in FOXP3 expression pattern observed in human and murine conventional CD4+ T 
lymphocytes. 
In addition, we investigated the effects of various culture conditions such as addition of TGF-
β and/or IL-10, on FOXP3 promoter methylation. Of note, no additional effects of these 
substances on promoter demethylation were observed. In contrast, addition of TGF-β during 
activation of murine naïve CD4+ T lymphocytes has been demonstrated to induce 
demethylation of the murine Foxp3 promoter as well as partial demethylation of the CNS3 
intronic region (Floess et al., 2007; Kim and Leonard, 2007). These results could indicate that 
TGF-β is more proficient at inducing a Tregs in mice consistent with in vitro findings (Chen et 
al., 2003; Tran et al., 2007). However, they may also reflect different responsiveness to low 
levels of TGF-β in humans versus mice, as the neutralization of this cytokine in the culture 
medium reportedly blocks the induction of transient FOXP3 expression in naïve human 
CD4+CD25- T lymphocytes (Tran et al., 2007). 
The unique FOXP3 promoter methylation profile in Tregs compared to conventional CD4+ T 
lymphocytes suggested that a demethylated pattern is a prerequisite for stable FOXP3 
expression and suppressive phenotype. This was one of the first reports regarding the epigenetic 
regulation of FOXP3 transcription. Since then, with expanding knowledge and technological 
advances within the field of epigenetics, extensive mapping of the chromatin landscape and 
methylation pattern in Treg versus conventional CD4+ T lymphocytes has deepened our 
understanding of the epigenetic control of the Treg lineage (Morikawa and Sakaguchi, 2014). 
Although most studies have been performed on mice, it is now clear that epigenetic 
modifications are crucial in Treg development, and currently represent the most specific marker 
of commitment to the Treg lineage available (Sakaguchi et al., 2013). 
4.2 FOXP3 AND SURVIVAL IN URINARY BLADDER CANCER (PAPER II) 
Urinary bladder cancer (UBC) is a malignancy highly associated to inflammation during its 
development and also harbors great potential for immunotherapeutic strategies as illustrated by 
the long-standing tradition of successful BCG treatment of superficial UBC (Herr and Morales, 
2008). In study II, the prognostic significance of tumor infiltrating CD3+ and FOXP3+ 
lymphocytes as well as tumor expression of FOXP3 was evaluated in a retrospective material 
of 37 patients with muscle invasive UBC. 
In accordance with previous studies in UBC and other malignancies, the presence of CD3+ 
tumor infiltrating lymphocytes (TIL) in the tumor was a positive prognostic factor for survival 
in our study (Galon et al., 2006; Lipponen et al., 1992; Zhang et al., 2003). This supports the 
notion that T lymphocytes are important players in the anti-tumor immune response to UBC 
and validates further studies to better understand how to potentiate this response in patients. 
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Somewhat to our surprise, FOXP3+ TIL were also associated to a better prognosis. In other 
malignancies, the results vary as to the prognostic significance of this population where some 
report a negative association to prognosis (e.g. hepatocellular cancer) and others positive 
correlations (e.g. colorectal cancer) (Gao et al., 2007; Salama et al., 2009). The fact that FOXP3 
is induced upon activation in conventional T helper lymphocytes could be one explanation for 
this apparent paradox, but it is also conceivable that anti-inflammatory effects may be 
beneficial to the patient in contexts where the inflammation as such acts to promote tumor 
progression (deLeeuw et al., 2012). 
In addition, we observed a distinct expression of FOXP3 in tumor cells in a subgroup of the 
patients (17/37) (Figure 6). Coherent with reports from other malignancies, this expression was 
not strictly confined to the nucleus, but also observed in the cytoplasm in some cases (Merlo et 
al., 2009). We found a long-term negative correlation between FOXP3 expression in tumor 
cells and survival, a finding that did not seem to be affected by the subcellular localization of 
the FOXP3 protein. This negative prognostic impact of FOXP3 expression by tumor cells has 
also been noted in several other forms of cancer, but the mechanisms behind this remains 
unclear (Triulzi et al., 2013). 
 Figure 6. Immunohistochemical evaluation of UBC tumors. (A) Tumor infiltrating 
lymphocytes expressing (A) CD3 or (B) FOXP3 (40x magnification). (C) 40x 
magnification of FOXP3 expression in tumor cells. (D) 100x magnification of FOXP3+ 
tumor cells with nuclear staining. 
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In conclusion, tumor infiltrating T lymphocytes are indeed important for patient outcome in 
urinary bladder cancer, as both CD3+ and FOXP3+ TIL were positively correlated to survival. 
The negative impact of tumor FOXP3 expression in urinary bladder cancer warrants further 
investigation to elucidate the biological impact of this expression on the tumor cells themselves 
as well as the consequent interactions with the immune system. 
4.3 ANTI-TUMOR IMMUNE REPONSES ARE SHAPED BY LOCATION AND 
THERAPY (PAPER III) 
As study II indicated a clear role for T lymphocytes in determining the prognosis of the disease 
in UBC, we set out to investigate the T lymphocyte immune response in more detail in a 
prospective study. In order to illuminate the effects of tumor-immune interactions on the T cell 
compartment at multiple levels, study III examines the immunophenotype of T lymphocytes in 
peripheral blood, tumor draining lymph nodes (sentinel node, SN), non-draining lymph nodes 
(non sentinel node, nSN) as well as tumor and macroscopically healthy bladder tissue. 
We demonstrate that the FOXP3+ fraction of CD4+ T lymphocytes was significantly increased 
in TIL populations as compared to all other locations. In addition, these CD4+FOXP3+ TIL T 
lymphocytes displayed high levels of the Treg effector markers surface CTLA-4 and CD39 as 
well as the activation and memory markers CD69, HLA-DR and CD45RO. Interestingly, this 
activated phenotype was to some extent mirrored by both CD4+FOXP3- and CD8+ TIL T 
lymphocytes. Furthermore, methylation analysis of tumor CD4+ TIL revealed a highly 
methylated FOXP3 promoter region despite the pronounced FOXP3 expression in these cells, 
in contrast to the CD4+ T lymphocyte population in peripheral blood where FOXP3 expression 
seemed to correlate better with the methylation level observed. Just as the previous study, these 
results indicate that the FOXP3+ TIL populations may represent an activated T lymphocyte 
subpopulation rather than committed Tregs. It is possible that the differing prognostic impact 
of FOXP3+ TILs in human cancers could relate to this finding (deLeeuw et al., 2012). Active 
recruitment of Treg to the tumor has been implied in other forms of cancer such as ovarian 
cancer, and were then associated to negative prognosis (Curiel et al., 2004). Notably, a recent 
study of tumor infiltrating Tregs in head and neck cancer, where this population also has been 
linked to worse prognosis (Sun et al., 2012), described elevated levels of immunosuppressive 
markers which correlated to more potent suppressor activity of these cells (Jie et al., 2013). 
Future studies comparing the epigenetic commitment and suppressive capacity of this subset 
in cancers with differing prognostic impact may help decipher the role of FOXP3+ TIL in 
humans. 
Since the immune infiltrates in tumors have been noted to differ also within the tumor itself 
(Fridman et al., 2012), we examined different tumor sublocalizations at the initial TUR-B. 
Interestingly, the invasive front (IF) of the tumor stood out with higher CD8+ T lymphocyte 
fraction compared to the central part (CP) or transitional zone (TZ) of the tumor. Furthermore, 
the IF also had a lower FOXP3+ fraction of CD4+ T lymphocyte in patients with muscle 
invasive disease. Thus again, higher FOXP3 appears to associate to better prognosis (lower 
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stage). Whether this association is linked to FOXP3 as an activation marker or directly to some 
immunomodulatory effect of these FOXP3+ cells remains to be investigated. 
In addition to direct anti-tumor effects, chemotherapy is known to potentiate immune responses 
by the induction of immunogenic cell death in the tumor (Krysko et al., 2012), and furthermore, 
different chemotherapeutic agents have been demonstrated to exert direct immunostimulatory 
effects (Maccubbin et al., 1992; Markasz et al., 2008). Interestingly, patients that had received 
chemotherapy in this study had higher lymph node T lymphocyte fractions compared to 
patients that had not received such therapy. Moreover, the neoadjuvant treated patients 
displayed higher T lymphocyte anti-tumor reactivity in their lymph nodes, as assessed with a 
flow cytometry based assay evaluating the proportion of blasting T lymphocytes to certain 
stimuli. Of note, a corresponding difference was not observed in the peripheral blood from 
these patients, in agreement with the hypothesis that the draining lymph nodes are the most 
probable sites for an anti-tumor response to be elicited. 
The prospective study design limits the conclusions that can be drawn from clinical parameters 
at this time due to at present relatively short follow-up time (3-18 months). In the future, it will 
be interesting to follow the disease in these patients and correlate clinical outcomes to the 
immunological parameters investigated. 
We conclude from this study that anti-tumor T lymphocyte responses are shaped by the 
environment in the different T lymphocyte compartments investigated, where T lymphocytes 
in lymph nodes and tumor display higher levels of both activation and effector suppressor 
markers. The greater anti-tumor reactivity in regional lymph nodes following chemotherapy 
suggests a future for therapeutic combinations of chemotherapy with adoptive T cell based 
immunotherapy of cancer.  
4.4 ADENOSINE RECEPTOR SIGNALING AFFECTS THE DEVELOPMENT OF 
TREG AND CONVENTIONAL T LYMPHOCYTES (PAPER IV) 
Given the recognized pronounced effects of adenosine receptor signaling in both tumor 
pathology and the immune system at large, we were interested in examining the impact of these 
receptors on the T lymphocyte compartment in mice, in order to set the base line for future 
studies in murine tumor models. Thus, in study IV, the influence of each individual adenosine 
receptor on the central and peripheral T lymphocyte compartments was evaluated in adenosine 
receptor knockout mice (A1R-/-, A2AR-/-, A2BR-/- and A3R-/-). 
Immunophenotyping was performed on thymus, spleen and lymph nodes, and compared to WT 
controls. In the thymus, there was an overall effect of knocking out any one of the four 
adenosine receptors, resulting in decreased fractions of CD4 and CD8 single positive 
thymocytes. The most pronounced effects were observed in A2BR-/- mice, which displayed a 
prominent reduction in cell yield from the thymus as well as alterations in relative and absolute 
numbers of thymic subpopulations. Previous studies in mice have implicated a role for A2AR 
signaling in the induction of apoptosis in DP thymocytes, but interestingly also depicted an 
A2AR independent role for adenosine signaling in inhibition of TCR induced activation of 
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thymocytes (Apasov et al., 2000). Furthermore, although the A2BR has the highest adenosine 
concentration threshold for induction intracellular of cAMP signaling, it has been shown to 
affect MAPK-signaling already at physiological adenosine concentrations (Schulte and 
Fredholm, 2000; Schulte and Fredholm, 2003a). In relation to the pronounced thymic 
phenotype of A2BR-/- mice, it is thus interesting to note that MAPK-signaling is essential during 
thymic selection and development of thymocytes (McNeil et al., 2005; Palmer, 2003). Since 
all four adenosine receptors can affect signaling via the MAPK pathway (Schulte and 
Fredholm, 2003b), it is possible that alterations in the balance of these receptors may explain 
their apparent non-redundant functions in thymic selection in our study. Interestingly, BM 
transfer to lethally irradiated WT hosts did not restore normal SP thymocyte frequencies, 
indicating that the changes observed were not attributable to the radioresistant stromal cells. 
The thymic CD4+Foxp3+Helios+ Treg population was also addressed and not surprisingly 
found to be decreased in number, given the reduced frequency of CD4SP thymocytes in all of 
the knockouts. Only the A1R-/- animals stood out with a reduced fraction of Foxp3+Helios+ 
CD4SP thymocytes, which normalized after bone marrow transfer to WT hosts, suggesting that 
adenosine A1R signaling in the thymic stromal cells may account for this part of the A1R-/- 
phenotype. This is in line with the fact that most studies describe very low expression level of 
the A1R in T lymphocytes (Bours et al., 2006). 
In the periphery, again the A2BR-/- animals stood out with reduced splenetic cell yield and T 
cell fraction as well as an altered CD4/CD8 ratio. The peripheral Treg compartment was also 
affected in these animals with the Foxp3+Helios+ fraction of CD4+ T lymphocytes found to 
approximately double of that found in WT mice. Of note, we observed a distinct Foxp3-Helios+ 
CD4+ T lymphocyte population, particularly in the spleen of A2BR-/- mice. In light of, the 
marked reduction in thymic cell count and reports linking Helios expression to activation and 
proliferation (Akimova et al., 2011), one could speculate that this population represents a 
peripheral expansion of T lymphocytes to compensate for the reduced thymic output. 
Interestingly, after bone marrow transfer to WT hosts, A2BR-/- T lymphocytes displayed normal 
CD4/CD8 ratio and peripheral T lymphocyte fractions, as well as an almost normalized 
Foxp3+Helios+ Treg fraction. This would suggest that adenosine A2BR signaling in the WT 
environment is largely able to rescue the peripheral T lymphocyte phenotype of A2BR-/- T 
lymphocytes, although the reduction in CD4SP thymocytes remained. 
It is clear that adenosine signaling contributes to the control of peripheral T lymphocyte 
responses via Treg dependent and independent mechanisms (Antonioli et al., 2013a). This 
study illustrates that also the thymic development of T lymphocytes is affected by abrogation 
of either one of the four adenosine receptors. In light of these findings, a more detailed 
examination of the functional consequences of adenosine receptor deletion in both Treg and 
conventional T lymphocyte subsets would be of great interest. 
 
  33 
5 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
Tregs are vital in the maintenance of peripheral self-tolerance and play a pivotal role in cancer 
immunology as demonstrated by the prognostic significance of these cells in several forms of 
cancer. The intriguing, and at first glance contradictory findings regarding the prognostic 
impact of FOXP3+ tumor infiltrating T lymphocytes, underscore the heterogeneity of this 
population and the importance of considering the whole immune contexture of the tumor 
(Fridman et al., 2012). Transient expression of FOXP3 in human activated T lymphocytes as 
well as the existence of FOXP3 splice variants in humans that are not present in mice deepen 
the complexity further and highlights the necessity to validate findings from murine models in 
humans. 
Our studies suggest that in the case of urinary bladder cancer, tumor infiltrating FOXP3+ CD4+ 
T lymphocytes do not represent committed tTreg, but rather a CD4+ conventional T 
lymphocyte population with induced expression of FOXP3. Still, FOXP3 expression in these 
cells is associated to high surface expression of effector Treg markers such as CD39 and 
CTLA-4, which indicates that these cells do harbor suppressive function. Since urinary bladder 
cancer development has been linked to chronic inflammation (Thompson et al., 2014), it may 
be that the positive prognostic impact associated with FOXP3+ TILs relates to suppression of 
this inflammatory response. Alternatively, given the methylated state of the FOXP3 promoter 
in these cells and the transient expression of FOXP3 upon activation in conventional CD4+ T 
lymphocytes, one could speculate that the observed FOXP3 expression mirrors a higher level 
of activation and thus anti-tumor responsiveness. Ongoing studies in our laboratory are 
currently addressing the functional suppressor capacity and expression profile of these tumor 
infiltrating Tregs. In light of the expanding view on T helper lineage plasticity (Weinmann, 
2014), it will also be of great interest to assess the cytokine profile and possible expression of 
transcription factors other than FOXP3 within this cell population. 
Increased understanding of the mechanisms that govern stable FOXP3 expression and a 
suppressive Treg phenotype, is instrumental for the development of future therapies targeting 
the Treg population. Multiple murine studies have illustrated the value of Treg depletion to 
augment anti-tumor immune responses in different cancer models, and in humans there are 
currently clinical trials underway that target this population by various mechanisms (Nishikawa 
and Sakaguchi, 2014), which stresses the importance to advance knowledge concerning the 
clinical impact and implications of Tregs in cancer. Furthermore, the same issues become of 
importance at the opposite end of the clinical spectrum, when attempting to harvest and expand 
Tregs for immunotherapy of autoimmunity. The evaluation of stable Treg commitment as 
opposed to the expression of FOXP3 in activated effector T lymphocytes, assessed by e.g. 
methylation analysis, is likely to be essential for the development of optimal expansion 
protocols. 
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As demonstrated by us and others (Jie et al., 2013), both Treg and conventional T lymphocyte 
populations appear to upregulate immunosuppressive markers in the context of the tumor. With 
this in mind, it is interesting to note the successful introduction of therapeutics designed to 
target co-inhibitory pathways such as ipilimumab (Hodi et al., 2010). However, the limited 
response rate combined with the autoimmune adverse effects of these treatments leave room 
for improvement (Weber et al., 2012). Since many pathways converge to elevate adenosine 
levels within the tumor, which in turn has been associated with immune suppression, 
modulation of adenosine signaling pathways represent a promising area of therapeutic 
development. Such approaches include CD39/CD73 inhibitors and A2AR antagonists that 
potentially could tip the balance between Treg and T effector cells in favor of an anti-tumor 
immune response (Bastid et al., 2013; Ohta and Sitkovsky, 2014). 
The immune effects of different conventional therapeutic regimens such as chemotherapy 
should also be considered in the evaluation of anti-tumor immune responses, as illustrated by 
study III in this thesis. Other studies have noted direct immunostimulatory effects of certain 
chemotherapeutic drugs in addition to their direct anti-tumor effects and promotion of 
immunogenic cell death (Krysko et al., 2012; Maccubbin et al., 1992; Markasz et al., 2008). In 
the clinical setting, further characterization of each of these different routes is essential to allow 
optimization of therapeutic protocols designed to promote the anti-tumor effects combined with 
the pro-immune effects as much as possible. 
In addition to immunotherapies aiming to enhance the anti-tumor immune response in vivo, 
multiple studies describing adoptive cell therapy of cancer have been reported (Dudley et al., 
2005; Karlsson et al., 2010; Qian et al., 2014; Sherif et al., 2010). Current adoptive 
immunotherapeutic strategies with in vitro expanded anti-tumor T lymphocytes have shown 
much promise but are cumbersome and still have a limited response rate in patients, possibly 
in part due to immune escape mechanisms employed by the tumor. It is tempting to speculate 
that the combination of adoptive T cell therapy with immunomodulatory strategies such as 
those discussed above may represent ways to overcome this local immune suppression. 
The immune system hosts great potential in the fight against cancer. Recent years have seen 
the emergence of many successful immunotherapies and undoubtedly more are still to come. 
All the same, a lot remains to be elucidated in the intricate interplay between tumor and immune 
cells. Further clarification of the immune contexture of human tumors will pave the road for 
new immunotherapeutic strategies and optimization of current clinical treatments to promote 
anti-tumor immunity. 
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6 POPULÄRVETENSKAPLIG SAMMANFATTNING 
I människokroppen pågår en ständig kamp för överlevnad där immunförsvaret kämpar för att 
försvara kroppens egna vävnader mot olika typer av faror såsom bakterier och virus. Samtidigt 
är förmågan att särskilja kroppens egna celler av yttersta vikt då oförmåga att upprätthålla 
tolerans mot dessa kan leda till immunattack mot kroppsegna organ, så kallad autoimmunitet. 
Cancerceller har förvärvat förändringar i sin arvsmassa, DNA, som dels ligger till grund för 
sjukdomsutvecklingen, men som också betyder att dessa celler uttrycker proteiner som till viss 
del är kroppsfrämmande. Dessa förändringar kan kännas igen av immunförsvaret som i det 
bästa scenariot identifierar förändrade celler redan på ett tidigt stadium och eliminerar dessa 
innan någon klinisk sjukdom hunnit bryta ut. Framgångrika tumörer utvecklar därför olika 
mekanismer för att undvika igenkänning. 
T celler är centrala spelare i både det specifika adaptiva immunförsvaret mot cancer och i 
upprätthållandet av tolerans mot kroppens egna vävnader. De så kallade regulatoriska T 
cellerna är essentiella för balansen i kroppens immunförsvar och kontrollen av det 
inflammatoriska svaret. Dessa celler karaktäriseras till stor del baserat på deras uttryck av 
proteinet FOXP3. I människor kompliceras dock studierna av dessa celler av att vanliga 
aktiverade T celler också visat sig kunna uttrycka detta protein. Den första studien i denna 
avhandling handlar om regleringen av FOXP3 uttryck i T celler. Här studerar vi så kallad 
epigenetik, vilket handlar om förändringar av kroppens arvsmassa som kan påverka 
proteinuttrycket i cellen, men som inte påverkar själva DNAsekvensen. En sådan förändring är 
tillägg av metylgrupper på DNAt (metylering). Generellt kan man säga att gener med en hög 
grad av metylering är mindre aktiva än ometylerade motsvarigheter. I vår första studie visar vi 
att regulatoriska T celler som kontinuerligt uttrycker FOXP3, har en ometylerad konfiguration 
i början av genen som kodar för detta protein, till skillnad från de vanliga T cellerna som är 
halvmetylerade i detta område. Som kontrast är B celler, som inte alls uttrycker FOXP3 helt 
metylerade. Vår slutsats från denna studie var att metyleringsgraden av FOXP3 genen kan 
förutspå ett kontinuerligt eller övergående uttryck av proteinet och således kan användas som 
en markör för stabila regulatoriska T celler. 
I nästa steg undersökte vi vilken effekt tumörinfiltrerande regulatoriska T celler har på den 
kliniska prognosen vid urinblåsecancer. Intressant nog fann vi att både T cellsinfiltration 
generellt och T celler som uttryckte proteinet FOXP3 förutspådde bättre prognos för 
patienterna. Detta kan tyckas motsägelsefullt då regulatoriska T celler generellt anses trycka 
ned det tumörspecifika immunförsvaret och således borde vara associerade till sämre prognos. 
I nuläget har dock många rapporter publicerats där betydelsen av tumörinfiltrerande 
regulatoriska T celler undersöks i olika former av cancer och det är tydligt att den prognostiska 
betydelsen kan variera alltifrån god till dålig. Orsakerna till detta är i nuläget inte helt klarlagda, 
men det tycks som om både tumörtyp och lokalisation kan spela en roll. Det har spekulerats att 
den goda prognoskopplingen i vissa cancerformer har att göra med kontroll av den kroniska 
inflammation som annars kan agera som en drivande faktor i tumörutvecklingen, alternativt 
skulle detta FOXP3 uttryck kunna vara en reflektion av allmän T cellsaktivering i 
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konventionella T celler. Intressant nog noterade vi även ett uttryck av FOXP3 i tumörceller hos 
en andel av patienterna. Detta uttryck var kopplat till sämre klinisk prognos, men de 
bakomliggande mekanismerna till detta är fortfarande oklara. 
För att vidare undersöka hur vanliga och regulatoriska T celler blir påverkade av tumören i 
urinblåsecancer, undersökte vi dessa cellpopulationer från blod, lymfknutor, och tumör med 
flödescytometri. De tumörinfiltrerande T cellerna generellt, men särskilt de regulatoriska T 
cellerna uppvisade en mycket hög aktiveringsgrad och uttryckte höga nivåer av proteiner som 
är aktiva vid nedreglering och kontroll av immunsvar. Intressant var också att vi fann skillnader 
i sammansättningen av de tumörinfiltrerande cellerna i olika delar av tumören, där den invasiva 
kanten stod ut i jämförelse med centrala delar av tumören. Vi fann att patienter med 
muskelinvasiva tumörer hade lägre andel FOXP3 uttryckande T celler vid den invasiva kanten 
jämfört med ytligt växande tumörer. Intressant nog visade sig de tumörinfiltrerande T cellerna 
vara till hög grad metylerade i sin FOXP3 gen, vilket tyder på att dessa celler inte representerar 
en dedikerade regulatoriska T celler utan snarare T celler med ett aktiveringsrelaterat uttryck 
av FOXP3. Dessutom noterade vi en tydlig effekt av genomgången cellgiftsbehandling på 
immunsvaret mot tumören, där denna behandling tycktes potentiera förmågan av T celler från 
tumördränerande lymfknutor att reagera på tumörproteiner. 
En metod som regulatoriska T celler utnyttjar för att kontrollera immunreaktioner är produktion 
av adenosin som i sig är immunhämmande i närmiljön. Det har visat sig att vissa tumörer också 
aktivt producerar adenosin, som kan hjälpa dessa att kontrollera ett eventuellt immunsvar mot 
tumören. För att studera vilka effekter adenosin har på T celler använde vi oss av så kallade 
knockoutmöss som saknar endera av de fyra definierade receptorerna för adenosin. I dessa 
möss karaktäriserade vi sedan T cellernas utveckling från deras utbildning i thymus (brässen) 
till deras sammansättning i mjälte och lymfknutor. Vi fann att adenosinsignalering tycks bidra 
till T cellsutveckling med både T cellsberoende och oberoende mekanismer. Vidare studier 
behövs för att utvärdera den funktionella betydelsen av dessa fynd. 
Sammanfattningsvis har dessa studier påvisat en epigenetisk signatur hos mänskliga 
regulatoriska T celler som kan användas för identifiering av denna population i patienter. 
Genom studier av denna cellpopulation hos patienter med urinblåsecancer har vi börjat 
kartlägga en del av de mekanismer som påverkar T cellssvaret och fortsatt prognos hos dessa 
patienter. Studier av T cellsutvecklingen i möss som saknar specifika adenosinreceptorer har 
belyst betydelsen av adenosinsignallering i thymus. Bättre förståelse för hur tumören 
interagerar med kroppens immunförsvar i patienter kan i kombination med grundläggande 
studier av hur regulatoriska system i kroppen fungerar, leda till nya behandlingsstrategier och 
sätt att väcka det immunförsvar som sövts av tumören. 
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